| Title: | Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk |
| Journal: | Blood Cancer Journal |
| Published: | 15 Jan 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38225345/ |
| DOI: | https://doi.org/10.1038/s41408-023-00974-9 |
| URL: | https://www.nature.com/articles/s41408-023-00974-9.pdf |
| Citations: | 2 (2 in last 2 years) as of 8 Aug 2024 |
Publication 8944
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP and mCAs at the same locus (e.g., transforming a heterozygous JAK2 CHIP mutation into a homozygous mutation through concomitant loss of heterozygosity at chromosome 9) might have important prognostic implications for malignancy transformation risk. We tested this hypothesis using our discovery cohort, the UK Biobank (n = 451,180), and subsequently validated it in the BioVU cohort (n = 91,335). We find that individuals with a concurrent somatic mutation and mCA were at significantly increased risk of hematologic malignancy (for example, In BioVU cohort incidence of hematologic malignancies is higher in individuals with co-occurring JAK2 V617F and 9p CN-LOH; HR = 54.76, 95% CI = 33.92-88.41, P < 0.001 vs. JAK2 V617F alone; HR = 44.05, 95% CI = 35.06-55.35, P < 0.001). Currently, the 'zygosity' of the CHIP mutation is not routinely reported in clinical assays or considered in prognosticating CHIP transformation risk. Based on these observations, we propose that clinical reports should include 'zygosity' status of CHIP mutations and that future prognostication systems should take mutation 'zygosity' into account.</p>
6 Keywords
- Chromosome Aberrations
- Clonal Hematopoiesis
- Hematologic Neoplasms
- Humans
- Mutation
- Point Mutation
18 Authors
- Ashwin Kishtagari
- M. A. Wasay Khan
- Yajing Li
- Caitlyn Vlasschaert
- Naimisha Marneni
- Alexander J. Silver
- Kelly von Beck
- Travis Spaulding
- Shannon Stockton
- Christina Snider
- Andrew Sochacki
- Dixon Dorand
- Taralynn M. Mack
- P. Brent Ferrell
- Yaomin Xu
- Cosmin A. Bejan
- Michael R. Savona
- Alexander G. Bick
Enabling scientific discoveries that improve human health